reports
- Luis de Toledo Heras
ITP INTERPARFUMS
RWE RWE AG
AALB AALBERTS N.V.
SEFER SERGEFERRARI GROUP SA
SSO SCATEC ASA
ENG ENAGAS SA
DGM DIAGNOSTIC MEDICAL SYSTEMS
GLPG GALAPAGOS NV
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
HOME NEINOR HOMES SA
GRE GRENERGY RENOVABLES
DSC1 DUTCH STAR C SHAR
OVH OVH GROUPE
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
PLNW PLANISWARE
ATO ATOS SE
- Luis de Toledo Heras
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ITP INTERPARFUMS
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
RWE RWE AG
01913 PRADA S.P.A.
AALB AALBERTS N.V.
MONC MONCLER SPA
SEFER SERGEFERRARI GROUP SA
SSO SCATEC ASA
ENG ENAGAS SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
DGM DIAGNOSTIC MEDICAL SYSTEMS
GLPG GALAPAGOS NV
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
HOME NEINOR HOMES SA
GRE GRENERGY RENOVABLES
DSC1 DUTCH STAR C SHAR
OVH OVH GROUPE
ALLFG ALLFUNDS (UK) LTD
ZGN ERMENEGILDO ZEGNA NV
FLOW FLOW TRADERS LTD
PLNW PLANISWARE
ATO ATOS SE
- Martial Descoutures
- Martial Descoutures
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Jacob Mekhael
Galapagos Intends to wind down cell therapy business
Galapagos announced its intention to wind down its cell therapy business following a strategic review. This follows a previous announcement of non-binding offers, subject to financing, where previous CEO Paul Stoffels emerged as one of the bidders for the business. This decision suggests external financing for the project has not been obtained, and we believe the decision to wind down the cell therapy business creates clarity and allows Galapagos to move forward with its new plans of building a ...
Galapagos Announces Intention to Wind Down Cell Therapy Business as Pa...
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its intention to wind down its cell therapy business and pursue new transformational business development transactions with its available cash resources. The in...
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen...
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen als onderdeel van de voortdurende transformatie van het bedrijf Deze intentie volgt na een uitgebreid strategisch evaluatieproces en zou de meest optimale manier zijn om kapitaal toe te wijzen ter ondersteuning van een sterkere en duurzame toekomst voor Galapagos Mechelen, België; 21 oktober 2025, 07:30 CET; gereglementeerde informatie – voorwetenschap – Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de intentie aan om haar celtherapieactiviteiten af te bouwen en met zijn beschikbare kasmiddelen nieuwe baanbre...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thibault Leneeuw
- Wim Lewi
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
Galapagos Announces Appointment of Fred Blakeslee as General Counsel Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. “We are very pleased to welcome Fred to the executive team,” said Henry Gosebruch, CEO of Galapagos. “He brings a unique combination of top-tier legal expertise, global business transaction experience, an...
Galapagos kondigt benoeming aan van Fred Blakeslee als General Counsel
Galapagos kondigt benoeming aan van Fred Blakeslee als General Counsel Mechelen, België; 16 oktober 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag de benoeming bekendgemaakt van de heer Fred Blakeslee tot Executive Vice President en General Counsel met ingang van 16 oktober 2025. Blakeslee volgt mevrouw Valeria Cnossen op, die het bedrijf zal verlaten na een korte transitieperiode. “We zijn erg blij Fred te mogen verwelkomen in het managementteam,” aldus Henry Gosebruch, CEO van Galapagos. “Hij combineert juridische expertise op topniveau met ruime ervaring in inter...
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2...
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained impact on patient outcomesMore than 40 abstracts across MG, CIDP, MMN, and IIM highlight depth of clinical evidence and ongoing commitment to rare neuromuscular disease communities October 15, 2025, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasda...
argenx announces Extraordinary General Meeting of Shareholders on Nove...
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the E...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
Galapagos Media reports Paul Stoffels behind non-binding offer for cel...
According to media reports, Paul Stoffels, Galapagos' previous CEO, has assembled a group of investors to bid for the company's cell therapy business. After joining Galapagos in 2022, Paul Stoffels pivoted the company towards cell therapies and focussed the company's efforts on de-centralised CAR-T manufacturing as a way to broaden access to such treatments. Following his resignation earlier this year, he now has placed a non-binding offer for the cell therapy business which is under strategic r...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Galapagos Receives non-binding offers for cell therapy business
Galapagos announced that it has received a limited number of non-binding offers from consortia, predominantly comprised of financial investors, to acquire the cell therapy business. The deadline for potential bidders to put forward binding, fully-financed, offers is in the coming weeks. The company will make an announcement on the outcome of the review of strategic alternatives for the cell therapy business no later than its 3Q25 update on 5 November 2025. € 37 TP and ACCUMULATE reiterated.
Galapagos Provides Update on Strategic Alternatives for Its Cell Thera...
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business (the “Cell Therapy Business”), including a potential divestiture of the Cell Therapy Business, with the goal of preserving shareholder value. As part of its review of strategic alternatives, over ...
Galapagos geeft update over strategische alternatieven voor haar celth...
Galapagos geeft update over strategische alternatieven voor haar celtherapieactiviteiten Mechelen, België; 1 oktober 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) en haar Raad van Bestuur hebben vandaag de volgende verklaring uitgegeven: Op 13 mei 2025 kondigde Galapagos aan dat haar Raad van Bestuur (de “Raad”) had besloten om alle strategische alternatieven voor haar celtherapieactiviteiten (de “Celtherapieactiviteiten”) te verkennen, met inbegrip van een mogelijke verkoop van de Celtherapieactiviteiten, met als doel het waarborgen van aandeelhouderswaarde. Als onderdeel...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.